These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 25475629)

  • 21. Meeting Report: 2013 PDA Virus & TSE Safety Forum.
    Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Hubbard BR; Kreil TR; Ruffing M; Ruiz S; Scott D; Silvester G
    PDA J Pharm Sci Technol; 2014; 68(3):193-214. PubMed ID: 25188343
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory approaches for control of viral contamination of vaccines.
    McClenahan S; Uhlenhaut C; Krause PR
    PDA J Pharm Sci Technol; 2011; 65(6):557-62. PubMed ID: 22294577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Report of the 2019 NIST-FDA workshop on standards for next generation sequencing detection of viral adventitious agents in biologics and biomanufacturing.
    Cleveland MH; Anekella B; Brewer M; Chin PJ; Couch H; Delwart E; Huggett J; Jackson S; Martin J; Monpoeho S; Morrison T; Ng SHS; Ussery D; Khan AS
    Biologicals; 2020 Mar; 64():76-82. PubMed ID: 32094072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Historical evaluation of the in vivo adventitious virus test and its potential for replacement with next generation sequencing (NGS).
    Barone PW; Keumurian FJ; Neufeld C; Koenigsberg A; Kiss R; Leung J; Wiebe M; Ait-Belkacem R; Azimpour Tabrizi C; Barbirato C; Beurdeley P; Brussel A; Cassart JP; Cote C; Deneyer N; Dheenadhayalan V; Diaz L; Geiselhoeringer A; Gilleece MM; Goldmann J; Hickman D; Holden A; Keiner B; Kopp M; Kreil TR; Lambert C; Logvinoff C; Michaels B; Modrof J; Mullan B; Mullberg J; Murphy M; O'Donnell S; Peña J; Ruffing M; Ruppach H; Salehi N; Shaid S; Silva L; Snyder R; Spedito-Jovial M; Vandeputte O; Westrek B; Yang B; Yang P; Springs SL
    Biologicals; 2023 Feb; 81():101661. PubMed ID: 36621353
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Massively parallel sequencing: a new tool in virus discovery and vaccine safety.
    Onions D
    Bull Mem Acad R Med Belg; 2011; 166(10-12):404-6. PubMed ID: 23082505
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk reduction in biotherapeutic products.
    Ill CR; Dehghani H
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):296-304. PubMed ID: 19333875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Report of the third conference on next-generation sequencing for adventitious virus detection in biologics for humans and animals.
    Khan AS; Mallet L; Blümel J; Cassart JP; Knezevic I; Ng SHS; Wall M; Jakava-Viljanen M; Logvinoff C; Goios A; Neels P
    Biologicals; 2023 Aug; 83():101696. PubMed ID: 37478506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Meeting report-workshop on spike characterizations and virus removal by filtration: trends and new developments.
    Willkommen H; Blümel J; Brorson K; Chen D; Chen Q; Gröner A; Hubbard BR; Kreil TR; Ruffing M; Ruiz S; Scott D; Silvester G
    PDA J Pharm Sci Technol; 2014; 68(3):215-20. PubMed ID: 25188344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of cells and biological reagents for adventitious agents using degenerate primer PCR and massively parallel sequencing.
    McClenahan SD; Uhlenhaut C; Krause PR
    Vaccine; 2014 Dec; 32(52):7115-21. PubMed ID: 25454874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adventitious agents in viral vaccines: lessons learned from 4 case studies.
    Petricciani J; Sheets R; Griffiths E; Knezevic I
    Biologicals; 2014 Sep; 42(5):223-36. PubMed ID: 25135887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Proceedings of the 2019 Viral Clearance Symposium, Session 7: Cell Banks and U.S. Pharmacopeia.
    O'Donnell S
    PDA J Pharm Sci Technol; 2022; 76(4):358-361. PubMed ID: 34911823
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current issues in viral assays and viral clearance evaluation.
    Lubiniecki AS
    Dev Biol Stand; 1996; 88():9-11. PubMed ID: 9119167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.
    Klug B; Robertson JS; Condit RC; Seligman SJ; Laderoute MP; Sheets R; Williamson AL; Gurwith M; Kochhar S; Chapman L; Carbery B; Mac LM; Chen RT;
    Vaccine; 2016 Dec; 34(51):6617-6625. PubMed ID: 27317264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficient extraction of adventitious virus nucleic acid using commercially available methods.
    Valiant WG; Borman J; Cai K; Vallone PM
    Biologicals; 2024 Feb; 85():101741. PubMed ID: 38157678
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adventitious Virus Detection in Cells by High-Throughput Sequencing of Newly Synthesized RNAs: Unambiguous Differentiation of Cell Infection from Carryover of Viral Nucleic Acids.
    Cheval J; Muth E; Gonzalez G; Coulpier M; Beurdeley P; Cruveiller S; Eloit M
    mSphere; 2019 Jun; 4(3):. PubMed ID: 31167947
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A history of adventitious agent contamination and the current methods to detect and remove them from pharmaceutical products.
    Valiant WG; Cai K; Vallone PM
    Biologicals; 2022 Oct; 80():6-17. PubMed ID: 36347754
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ensuring the safety of vaccine cell substrates by massively parallel sequencing of the transcriptome.
    Onions D; Côté C; Love B; Toms B; Koduri S; Armstrong A; Chang A; Kolman J
    Vaccine; 2011 Sep; 29(41):7117-21. PubMed ID: 21651935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Detection of adventitious viruses in biologicals--a rare occurrence.
    Nims RW
    Dev Biol (Basel); 2006; 123():153-64; discussion 183-97. PubMed ID: 16566443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.